A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.

Animals Antiviral Agents / pharmacokinetics Dengue / drug therapy Dengue Virus / classification Disease Models, Animal Female Male Membrane Proteins / antagonists & inhibitors Mice RNA Helicases / antagonists & inhibitors Serine Endopeptidases / metabolism Viral Load / drug effects Viral Nonstructural Proteins / antagonists & inhibitors Viremia / drug therapy Virus Replication / drug effects

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
10 2021

Historique:

received: 30 06 2020

accepted: 01 09 2021

pubmed: 8 10 2021

medline: 27 1 2022

entrez: 7 10 2021

Statut: ppublish

Résumé

Dengue virus causes approximately 96 million symptomatic infections annually, manifesting as dengue fever or occasionally as severe dengue

Identifiants

DOI: 10.1038/s41586-021-03990-6 PMID: 34616043

pubmed: 34616043

doi: 10.1038/s41586-021-03990-6

pii: 10.1038/s41586-021-03990-6

doi:

Substances chimiques

Antiviral Agents 0

Membrane Proteins 0

NS3 protein, flavivirus 0

NS4B protein, Dengue virus 0

Viral Nonstructural Proteins 0

Serine Endopeptidases EC 3.4.21.-

RNA Helicases EC 3.6.4.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

504-509

Commentaires et corrections

Type : CommentIn

Type : ErratumIn

Type : CommentIn

Informations de copyright

Références

Dengue and Severe Dengue. World Health Organization, https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue (15 April 2019).

Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504–507 (2013).

doi: 10.1038/nature12060

Ayukekbong, J. A., Oyero, O. G., Nnukwu, S. E., Mesumbe, H. N. & Fobisong, C. N. Value of routine dengue diagnosis in endemic countries. World J. Virol. 6, 9–16 (2017).

doi: 10.5501/wjv.v6.i1.9

Paixão, E. S., Teixeira, M. G. & Rodrigues, L. C. Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases. BMJ Glob. Health 3, e000530 (2018).

doi: 10.1136/bmjgh-2017-000530

Simmons, C. P., Farrar, J. J., van Nguyen, V. & Wills, B. Dengue. N. Engl. J. Med. 366, 1423–1432 (2012).

doi: 10.1056/NEJMra1110265

Messina, J. P. et al. The current and future global distribution and population at risk of dengue. Nat. Microbiol. 4, 1508–1515 (2019).

doi: 10.1038/s41564-019-0476-8

Duong, V. et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc. Natl Acad. Sci. USA 112, 14688–14693 (2015).

doi: 10.1073/pnas.1508114112

ten Bosch, Q. A. et al. Contributions from the silent majority dominate dengue virus transmission. PLoS Pathog. 14, e1006965 (2018).

doi: 10.1371/journal.ppat.1006965

Halstead, S. B. Pathogenesis of dengue: dawn of a new era. F1000Research 4, 1353 (2015).

doi: 10.12688/f1000research.7024.1

Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932 (2017).

doi: 10.1126/science.aan6836

Dengue vaccine: WHO position paper—July 2016. Wkly Epidemiol. Rec. 91, 349-364 (2016).

Wilder-Smith, A. et al. Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect. Dis. 19, e31–e38 (2019).

doi: 10.1016/S1473-3099(18)30494-8

Dengue vaccine: WHO position paper—September 2018. Wkly Epidemiol. Rec. 93, 457–476 (2018).

Low, J. G., Gatsinga, R., Vasudevan, S. G. & Sampath, A. In Dengue and Zika: Control and Antiviral Treatment Strategies. Advances in Experimental Medicine and Biology (eds Hilgenfeld, R. & Vasudevan, S. G.) 319–332 (Springer, 2018).

Whitehorn, J. et al. Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions. PLoS Negl. Trop. Dis. 8, e3025 (2014).

doi: 10.1371/journal.pntd.0003025

Bardiot, D. et al. Discovery of indole derivatives as novel and potent dengue virus inhibitors. J. Med. Chem. 61, 8390–8401 (2018).

doi: 10.1021/acs.jmedchem.8b00913

Schmid, M. A. & Harris, E. Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. PLoS Pathog. 10, e1004541 (2014).

doi: 10.1371/journal.ppat.1004541

Touret, F. et al. Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug. Antiviral Res. 168, 109–113 (2019).

doi: 10.1016/j.antiviral.2019.05.005

Płaszczyca, A. et al. A novel interaction between dengue virus nonstructural protein 1 and the NS4A-2K–4B precursor is required for viral RNA replication but not for formation of the membranous replication organelle. PLoS Pathog. 15, e10077362019 (2019).

doi: 10.1371/journal.ppat.1007736

Chatel-Chaix, L. et al. A combined genetic–proteomic approach identifies residues within dengue virus NS4B critical for interaction with NS3 and viral replication. J. Virol. 89, 7170-7186 (2015).

doi: 10.1128/JVI.00867-15

Moquin, S. A. et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci. Transl. Med. 13, eabb2181 (2021).

doi: 10.1126/scitranslmed.abb2181

Clapham, H. E., Tricou, V., Van Vinh Chau, N., Simmons, C. P. & Ferguson, N. M. Within-host viral dynamics of dengue serotype 1 infection. J. R. Soc. Interface 11, 20140094 (2014).

doi: 10.1098/rsif.2014.0094

Sim, S. et al. Tracking dengue virus intra-host genetic diversity during human-to-mosquito transmission. PLoS Negl. Trop. Dis. 9, e0004052 (2015).

doi: 10.1371/journal.pntd.0004052

Simmons, C. P. et al. Recent advances in dengue pathogenesis and clinical management. Vaccine 33, 7061–7068 (2015).

doi: 10.1016/j.vaccine.2015.09.103

Nguyen, N. M. et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc. Natl Acad. Sci. USA 110, 9072–9077 (2013).

doi: 10.1073/pnas.1303395110

Simmons, C. P. et al. Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl. Trop. Dis. 6, e1752 (2012).

doi: 10.1371/journal.pntd.0001752

Low, J. G., Ooi, E. E. & Vasudevan, S. G. Current status of dengue therapeutics research and development. J. Infect. Dis. 215, S96–S102 (2017).

doi: 10.1093/infdis/jiw423

Unlocking the Potential of Preventive Therapies for Malaria. World Health Organization, https://www.who.int/malaria/media/preventive-therapies/en/ (7 April 2017).

Zou, J. et al. Characterization of dengue virus NS4A and NS4B protein interaction. J. Virol. 89, 3455–3470 (2015).

doi: 10.1128/JVI.03453-14

Miller, S., Sparacio, S. & Bartenschlager, R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J. Biol. Chem. 281, 8854–8863 (2006).

doi: 10.1074/jbc.M512697200

Chatel-Chaix, L. et al. Dengue virus perturbs mitochondrial morphodynamics to dampen innate immune responses. Cell Host Microbe 20, 342–356 (2016).

doi: 10.1016/j.chom.2016.07.008

Zmurko, J., Neyts, J. & Dallmeier, K. Flaviviral NS4B, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. Rev. Med. Virol. 25, 205–223 (2015).

doi: 10.1002/rmv.1835

Umareddy, I., Chao, A., Sampath, A., Gu, F. & Vasudevan, S. G. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J. Gen. Virol. 87, 2605–2614 (2006).

doi: 10.1099/vir.0.81844-0

Janssen Pharmaceuticals & KU Leuven. Preparation of mono- or di-substituted derivatives as dengue viral replication inhibitors. Patent WO/2016/050841 (2016).

Janssen Pharmaceuticals & KU Leuven. Preparation of mono- or di-substituted derivatives as dengue viral replication inhibitors. Patent WO/2016/050831 (2016).

Janssen Pharmaceuticals & KU Leuven. Preparation of substituted indoline derivatives as dengue viral replication inhibitors. Patent WO/2017/167951 (2017).

Novartis. N-substituted tetrahydrothienopyridine derivatives as antiviral agents and their preparation. Patent WO/2019/244047 (2019).

Fischl, W. & Bartenschlager, R. High-throughput screening using dengue virus reporter genomes. Methods Mol. Biol. 1030, 205–219 (2013).

doi: 10.1007/978-1-62703-484-5_17

Aubry, F. et al. Single-stranded positive-sense RNA viruses generated in days using infectious subgenomic amplicons. J. Gen. Virol. 95, 2462–2467 (2014).

doi: 10.1099/vir.0.068023-0

Kum, D. B. et al. A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. NPJ Vaccines 3, 56 (2018).

doi: 10.1038/s41541-018-0092-2

De Burghgraeve, T. et al. 3′,5′Di-O-trityluridine inhibits in vitro flavivirus replication. Antiviral Res. 98, 242–247 (2013).

doi: 10.1016/j.antiviral.2013.01.011

Kaptein, S. J. F. et al. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob. Agents Chemother. 54, 5269–5280 (2010).

doi: 10.1128/AAC.00686-10

Verbist, B. M. et al. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering. Bioinformatics 31, 94–101 (2015).

doi: 10.1093/bioinformatics/btu587

Münster, M. et al. A reverse genetics system for Zika virus based on a simple molecular cloning strategy. Viruses 10, E368 (2018).

doi: 10.3390/v10070368

Zmurko, J. et al. The viral polymerase inhibitor 7-deaza-2′-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. 10, e0004695 (2016).

doi: 10.1371/journal.pntd.0004695

Jaki, T. & Wolfsegger, M. J. Estimation of pharmacokinetic parameters with the R package PK. Pharm. Stat. 10, 284–288 (2011).

doi: 10.1002/pst.449